Cell therapy--back on the up-curve. Interview with Paul Kemp by Elisa Manzotti.
Intercytex is an emerging healthcare company developing cell therapy products for the wound care and aesthetic medicine markets. The company, based in Cambridge, UK, commenced operations in 2000 and has raised over 31 million pounds in four private equity funding rounds. It is using its proprietary expertise in cell therapy to develop products that harness the innate ability of human cells to regenerate and repair the body. Here, founder and Chief Scientific Officer of Intercytex, Dr Paul Kemp, reflects on current status and future prospects for cell therapy with Regenerative Medicine's Elisa Manzotti. Dr Kemp was formerly Vice President of Research at Organogenesis, Inc. and has more than 17 years' experience in the commercial development of cell therapy. In this interview, Dr Kemp draws attention to a cycle that so often characterizes novel medical research: initial hype, a subsequent trough of disappointment and final emergence of viable technology. He explains how cell therapy is now emerging from the trough to become a rational, real and successful component of modern medicine.
Kemp
Paul
P
D002056:Burns / Q000628:therapy; D064987:Cell- and Tissue-Based Therapy / Q000266:history* / Q000639:trends*; D004345:Drug Industry / Q000331:legislation & jurisprudence; D033161:Government Regulation; D049673:History, 20th Century; D049674:History, 21st Century; D044968:Regenerative Medicine / Q000379:methods / Q000639:trends; D023822:Tissue Engineering / Q000191:economics / Q000266:history / Q000331:legislation & jurisprudence / Q000639:trends; D014947:Wounds and Injuries / Q000628:therapy